Table 2.
Actual antibiotic and health care resource use
| All UAE patients (N=24) |
IV-to-PO switch (N=5) |
IV-only (N=19) |
|
|---|---|---|---|
| Number of MRSA-targeted lines of therapy, n(%) | |||
| 1 | 16 (66.7%) | 0 (0.0%) | 16 (84.2%) |
| 2 | 5 (20.8%) | 3 (60.0%) | 2 (10.5%) |
| 3 | 3 (12.5%) | 2 (40.0%) | 1 (5.3%) |
| MRSA-active length of therapy (including PO), mean ± SD | 10.8±7.0 | 12.6±7.4 | 10.4±7.1 |
| MRSA-active IV days, mean (SD) | 9.8±6.6 | 7.4±4.6 | 10.4±7.1 |
| MRSA-targeted antibiotics used in initial line, n (%) | |||
| Clindamycin IV | 4 (16.7%) | 2 (40.0%) | 2 (10.5%) |
| Linezolid IV | 4 (16.7%) | 0 (0.0%) | 4 (21.1%) |
| Meropenem IV | 1 (4.2%) | 0 (0.0%) | 1 (5.3%) |
| Teicoplanin IV | 2 (8.3%) | 0 (0.0%) | 2 (10.5%) |
| Tigecycline IV | 1 (4.2%) | 1 (20.0%) | 0 (0.0%) |
| Vancomycin IV | 8 (33.3%) | 2 (40.0%) | 6 (31.6%) |
| Tigecycline IV + Vancomycin IV | 1 (4.2%) | 0 (0.0%) | 1 (5.3%) |
| MRSA-targeted antibiotics used in last line, n (%) | |||
| Clindamycin IV | 2 (8.3%) | 0 (0.0%) | 2 (10.5%) |
| Clindamycin PO | 1 (4.2%) | 1 (20.0%) | 0 (0.0%) |
| Linezolid IV | 5 (20.8%) | 0 (0.0%) | 5 (26.3%) |
| Linezolid PO | 3 (12.5%) | 3 (60.0%) | 0 (0.0%) |
| Meropenem IV | 1 (4.2%) | 0 (0.0%) | 1 (5.3%) |
| TMP/SMX PO | 1 (4.2%) | 1 (20.0%) | 0 (0.0.%) |
| Teicoplanin IV | 2 (8.3%) | 0 (0.0%) | 2 (10.5%) |
| Tigecycline IV | 2 (8.3%) | 0 (0.0%) | 2 (10.5%) |
| Vancomycin IV | 6 (25%) | 0 (0.0%) | 6 (31.6%) |
| Tigecycline IV + Vancomycin IV | 1 (4.2%) | 0 (0.0%) | 1 (5.3%) |
| MRSA-targeted antibiotics prescribed at discharge | 8 (33.3%) | 3 (60%) | 5 (26.3%) |
| Ciprofloxacin POa | 1 (12.5%) | 0 (0.0%) | 1 (20%) |
| Clindamycin POa | 1 (12.5%) | 1 (33.3%) | 0 (0.0%) |
| Doxycycline POa | 1 (12.5%) | 0 (0.0%) | 1 (20.0%) |
| Linezolid POa | 3 (37.5%) | 1 (33.3%) | 2 (40.0%) |
| Trimethoprim POa | 1 (12.5%) | 1 (33.3%) | 0 (0.0%) |
| TMP/SMX POa | 1 (12.5%) | 0 (0.0%) | 1 (20.0%) |
| LOS, days from cSSTI index through discharge, mean (SD) | 13.9±9.3 | 14.2±7.6 | 13.8±9.8 |
| Regular ward days, mean (SD) | 10.3±8.9 | 14.2±7.6 | 9.3±9.1 |
| High dependency/intermediate care days, mean (SD) | 2.9±8.3 | 0±0 | 3.6±9.3 |
| Intensive care unit days, mean (SD) | 0.6±3.1 | 0±0 | 0.8±3.4 |
| Surgical procedures for cSSTI treatment, n (%) | 21 (87.5%) | 5 (100.0%) | 16 (84.2%) |
| Total number of procedures among those with any procedures, mean ± SD | 1.1 ±0.6 | 1.2±0.4 | 1.1 ±0.6 |
Note:
a
Denominator is patients with any MRSA-targeted antibiotic prescribed at discharge.
Abbreviations: cSSTI, complicated skin and soft tissue infection; IV, intravenous; LOS, length of stay; MRSA, methicillin-resistant Staphylococcus aureus; PO, oral; SD, standard deviation; TMP/SMX, trimethoprim/sulfamethoxazole; UAE, United Arab Emirates.